Working… Menu

Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01512862
Recruitment Status : Unknown
Verified April 2012 by Yon Su Kim, Seoul National University Hospital.
Recruitment status was:  Recruiting
First Posted : January 19, 2012
Last Update Posted : April 10, 2012
Information provided by (Responsible Party):
Yon Su Kim, Seoul National University Hospital

Brief Summary:

Proteinuria is not only a marker of chronic kidney disease (CKD) progression, but also a marker of cardiovascular disease and death. In previous studies, active vitamin D deficiency is associated with cardiovascular risk factors such as albuminuria, diabetes mellitus, and lower glomerular filtration rate (GFR). And calcitriol was shown to have a preventive effect in progressive glomerular damage in a renal ablation model. Calcitriol, an active form of vitamin D (1,25-dihydroxyvitamin-D3), is commonly used for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney diseases.

Therefore, the objective of this study is to evaluate the anti-proteinuric effect of calcitriol in non-diabetic kidney disease patients. They will be treated with calcitriol and placebo for 24 weeks and observed for 24 weeks after treatment. Proteinuria, renal function, serum and urinary inflammatory markers, and adverse event will be monitored.

Condition or disease Intervention/treatment Phase
Proteinuria Drug: Calcitriol Drug: Placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Additive Renoprotective Effects of Oral Calcitriol in Nondiabetic Chronic Kidney Disease Patients
Study Start Date : January 2012
Estimated Primary Completion Date : December 2012
Estimated Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases
Drug Information available for: Calcitriol

Arm Intervention/treatment
Experimental: Calcitriol Drug: Calcitriol
Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
Other Name: Calcio® (Hanmi Pharm Co., Korea)

No Intervention: Placebo Drug: Placebo
Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months

Primary Outcome Measures :
  1. Changes in proteinuria [ Time Frame: 6, 12 months after administration ]
    Comparison of proteinuria amount checked by random urine protein/creatinine ratio

Secondary Outcome Measures :
  1. Changes in renal function [ Time Frame: 3, 6, 9 and 12 months ]
    Comparison of in serum creatinine level from baseline

  2. Changes in urinary renal damage markers [ Time Frame: 6, 12 months ]
    Comparison of urinary TGF-beta, TNF-alpha, MCP-1 level from baseline

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Nondiabetic kidney disease patients aged 19-70 years
  • MDRD GFR ≥ 30 mL/min/1.73m2
  • Patients with residual urine protein/creatinine ratio > 200 mg/g
  • Adequate blood pressure control as treated systolic blood pressure <=140 or diastolic <=90 mmHg with RAS inhibitor for more than 3 months
  • Normotensive patients untreated with RAS inhibitors
  • Serum intact PTH as 35-500 mg/dL and serum calcium less than 10.2 mg/dL
  • Patients who have not been treated vitamin D within the 3 months prior to signing the informed consent form

Exclusion Criteria:

  • Patients with nephrotic-range proteinuria (24 hour urine protein >3.5 g/24 hr)
  • Patients with rapidly progressive glomerulonephritis
  • Patients requiring renal replacement therapy immediately
  • Hypercalcemia (uncorrected serum calcium level > 10.2 mg/dL) within 3 months
  • Malignant hypertension
  • Heart failure (New York Heart Association [NYHA] functional class II to IV or LVEF less than 40%)
  • Severe chronic obstructive lung disease
  • Decompensated liver disease
  • Known allergy or hypersensitivity to vitamin D
  • Current treatment with steroids and/or immunosuppressive agents
  • No other active primary malignancy requiring treatment or that limits survival to ≤ 2 years
  • History of noncompliance to medical regimen
  • Inability to give an informed consent or to cooperate with researchers (e.g., psychiatric disorder)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01512862

Layout table for location contacts
Contact: Nayoung Han, M.S. +82-2-2072-0335

Layout table for location information
Korea, Republic of
Seoul National University Bundang Hospital Enrolling by invitation
Seongnam, Gyeonggi-do, Korea, Republic of, 463-707
Seoul National University Hospital Recruiting
Seoul, Korea, Republic of, 110-744
Contact: Yon Su Kim, M.D., Ph.D.    82-2-2072-2264   
Contact: Dong Ki Kim, M.D., Ph.D.    82-2-2072-2303   
Principal Investigator: Yon Su Kim, M.D., Ph.D.         
Sub-Investigator: Dong Ki Kim, M.D., Ph.D.         
Sub-Investigator: Nayoung Han, M.S.         
SMG-SNU Boramae Medical Center Enrolling by invitation
Seoul, Korea, Republic of, 156-707
Sponsors and Collaborators
Seoul National University Hospital
Layout table for investigator information
Study Chair: Jung Mi Oh, Pharm.D. Seoul National Univerisy College of Pharmacy
Principal Investigator: Yon Su Kim, M.D., Ph.D. Seoul National University Hospital
Layout table for additonal information
Responsible Party: Yon Su Kim, Professor, Seoul National University Hospital Identifier: NCT01512862    
Other Study ID Numbers: SNUH-CCTO
First Posted: January 19, 2012    Key Record Dates
Last Update Posted: April 10, 2012
Last Verified: April 2012
Keywords provided by Yon Su Kim, Seoul National University Hospital:
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Urologic Diseases
Urination Disorders
Urological Manifestations
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Calcium Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents
Growth Substances
Bone Density Conservation Agents